HKEX: 1244
Interim Report 2026
Earlier from 3d Medicines
- 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
- 3D Medicines Inc Says Zhang Jing Resigns As CFO
- 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
- 3D Medicines Says Envafoimab Granted Orphan Drug Designation